TIMP3

Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis

Retrieved on: 
Thursday, September 14, 2023
Antigen, Idiopathic disease, Nidogen, Drug development, Idiopathic pulmonary fibrosis, NASH, Culture, E pluribus unum, MHC, Cancer, Proteomics, Cathepsin B, TIMP3, Chronic obstructive pulmonary disease, Asporin, Lung transplantation, Protein, Keratin, Patient, Fatty liver disease, Integrin, Artificial intelligence, Conditional sentence, HEPA, IPF, Pharmaceutical industry, Vaccine, Dietary supplement

EDISON, N.J., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced positive results from a translational research study in which Hepion’s lead drug candidate, rencofilstat, was administered to diseased human lung tissue from patients with idiopathic pulmonary fibrosis (“IPF”).

Key Points: 
  • In this study, FibroFind Ltd. (Newcastle, UK) obtained diseased lung tissue from two individuals undergoing lung transplantation for end-stage IPF, a deadly fibrotic lung disease.
  • Precision cut lung slices (PCLuS) were made and individually incubated in culture with rencofilstat, nintedanib, pirfenidone, or combinations of the compounds for four days.
  • Quantitative proteomic characterization of lung tissue in idiopathic pulmonary fibrosis.
  • Quantitative proteomic characterization of the lung extracellular matrix in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting

Retrieved on: 
Friday, November 12, 2021
Safety, SITC, Cancer, Private Securities Litigation Reform Act, Therapy, GPS, TIMP3, Toxicity, Cytokine, NHP, U.S. Securities and Exchange Commission, Engineering, Therapeutic index, Prospectus, Disease, Immune system, Food, Matrix metalloproteinase, Society, Society for Immunotherapy of Cancer, COVID-19, Goal, Research, Tumor microenvironment, Regulation of tobacco by the U.S. Food and Drug Administration, Program, MMP, Neoplasm, Biotechnology, GLOBE, Data, SEC, Mouse, Immunotherapy, Poster, Patent, Patient, FDA, Pharmaceutical industry, Vaccine

These data are highlighted in a poster at the Society for Immunotherapy in Cancers 36th Annual Meeting (SITC), which is being held virtually and in Washington, D.C., from November 10-14, 2021.

Key Points: 
  • These data are highlighted in a poster at the Society for Immunotherapy in Cancers 36th Annual Meeting (SITC), which is being held virtually and in Washington, D.C., from November 10-14, 2021.
  • Using our GPS platform, we have engineered XTX301 to achieve systemic delivery of tumor-selective IL-12, while avoiding the known side effect challenges.
  • These preclinical data showcase our engineering efforts to activate XTX301 only when it is within the tumor microenvironment, resulting in the potential to achieve an optimized therapeutic index and enhanced anti-tumor activity.
  • Except as required by law, Xilio Therapeutics explicitly disclaims any obligation to update any forward-looking statements.